EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.


You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free